Company Filing History:
1 out of 512 
1 out of 8 Years Active: 2025
Title: Jose Manuel Baselga Torres: Innovator in Cancer Therapy
Introduction
Jose Manuel Baselga Torres is a prominent inventor based in New York, NY (US). He has made significant contributions to the field of cancer therapy through his innovative research and development of targeted drug delivery systems. His work focuses on improving the efficacy of PI3K inhibitors, which are crucial in the treatment of various proliferative diseases, including cancer.
Latest Patents
Jose Manuel Baselga Torres holds a patent for "PI3K inhibitors and uses thereof." This patent represents a significant advancement in cancer therapy by developing a new, targeted drug delivery paradigm. The patent includes compounds such as those of Formula (I) and (II), along with their pharmaceutically acceptable salts, hydrates, solvates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs. These PI3K inhibitors, particularly PI3Kα inhibitors, are designed for the treatment and prevention of various diseases, especially cancer. Additionally, the patent describes nanoparticles and nanogels that encapsulate these compounds for targeted delivery to cancer cells or tumors.
Career Highlights
Throughout his career, Jose Manuel Baselga Torres has worked with esteemed institutions such as the Sloan Kettering Institute for Cancer Research and the Tri-Institutional Therapeutics Discovery Institute. His research has been pivotal in advancing cancer treatment methodologies and improving patient outcomes.
Collaborations
Jose has collaborated with notable colleagues in the field, including Makoto Fushimi and Maurizio Scaltriti. Their combined expertise has contributed to the development of innovative therapeutic strategies in cancer research.
Conclusion
Jose Manuel Baselga Torres is a key figure in the advancement of cancer therapy through his innovative work on PI3K inhibitors. His contributions have the potential to significantly impact the treatment of cancer and improve the lives of many patients.